therapeutically effective amount of a compound according to any one of Claims 1 through 15.

23. A method according to Claim 22 wherein said patient is a human.

24. A method according to Claim 23 wherein said patient is a postmenopausal female.

25. A method according to any of Claims 22 through 24 wherein the disease associated with an aberrant physiological response to endogenous estrogen is estrogen dependent cancer.

26. A method according to Claim 25 wherein said cancer is breast cancer.

27. A method according to any of Claims 22 through 24 wherein the disease associated with an aberrant physiological response to endogenous estrogen is endometriosis.

28. A method according to any of Claims 22 through 24 wherein the disease associated with an aberrant physiological response to endogenous estrogen is uterine fibrosis.

29. A compound of the formula



(3)

wherein

R^{1a} is –H or –Opg, wherein Pg is a hydroxy protecting group;

R^{0a}, R^{2a}, and R^{3a} are independently R^{1a} or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3; and

Y is –O-, -S-, -NH-, -NMe-, or $-CH_2-$;

or a pharmaceutically acceptable salt thereof.

30. A compound according to Claim 29 wherein said compound is (2-benzyl-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; or a pharmaceutically acceptable salt thereof.

31. A compound of the formula



(4)

wherein

R^{1a} is –H or –Opg, wherein Pg is a hydroxy protecting group;

R^{0a}, R^{2a}, and R^{3a} are independently R^{1a} or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3; and

Y is –O-, -S-, -NH-, -NMe-, or $-CH_2-$;

or a pharmaceutically acceptable salt thereof.

32. A compound according to Claim 31 wherein said compound is (2-benzyl-6-methoxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanol; or a pharmaceutically acceptable salt thereof.

33. A compound of the formula



(9)

wherein

R^{1a} is –H or –Opg, wherein Pg is a hydroxy protecting group;

R^{0a}, R^{2a}, and R^{3a} are independently R^{1a} or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3; and

Y is –O-, -S-, -NH-, -NMe-, or $-CH_2-$;

or a pharmaceutically acceptable salt thereof.

34. A compound according to Claim 33 wherein said compound is [2-(4-fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; or a pharmaceutically acceptable salt thereof.

35. A compound of the formula



(10)

wherein

R^{1a} is –H or –Opg, wherein Pg is a hydroxy protecting group;

R^{0a}, R^{2a}, and R^{3a} are independently R^{1a} or halo;

R^4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;

n is 2 or 3; and

Y is –O-, -S-, -NH-, -NMe-, or $-CH_2-$;

or a pharmaceutically acceptable salt thereof.

36. A compound according to Claim 35 wherein said compound is [2-(4-fluoro-benzyl)-6-methoxy-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanol; or a pharmaceutically acceptable salt thereof.

37. The use of a compound according to any of Claims 1 to 15 for the manufacture of a medicament.

38. The use of a compound according to any of Claims 1 to 15 for the manufacture of a medicament for inhibiting a disease associated with estrogen deprivation.

39. The use according to Claim 38 wherein said disease is bone loss.

40. The use according to Claim 38 wherein said disease is cardiovascular disease.

41. The use of a compound according to any of Claims 1 to 15 for the manufacture of a medicament for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.

42. The use according to Claim 41 wherein said disease is estrogen dependent cancer.

43. The use according to Claim 42 wherein said cancer is breast cancer.

44. The use according to Claim 41 wherein the disease associated with an aberrant physiological response to endogenous estrogen is endometriosis.

45. The use according to Claim 41 wherein the disease associated with aberrant physiological response to endogenous estrogen is uterine fibrosis.

46. A pharmaceutical composition for inhibiting a disease associated with deprivation containing as an active ingredient a compound according to Claims 1 to 15.

47. A pharmaceutical composition for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen containing as an active ingredient a compound according to any of Claims 1 to 15.